EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acylcarnitine and Free Fatty Acid Profiles in Primary Biliary Cholangitis: Associations with Fibrosis and Inflammation

Magdalena Rogalska, Agnieszka Błachnio-Zabielska, Piotr Zabielski iD, Jacek Robert Janica iD, Kamila Roszczyc-Owsiejczuk, Karolina Pogodzińska, Aleksandra Andrzejuk, Andrzej Dąbrowski, Robert Flisiak iD, Paweł Rogalski

Nutrients · 2025

DOI: 10.3390/nu17071097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Magdalena Rogalska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 15-089 Białystok, Poland. Hauptthemen laut MEDLINE: Carnitine, Liver Cirrhosis, Biliary, Inflammation, Fatty Acids, Nonesterified. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by bile duct destruction, cholestasis, and fibrosis. Acylcarnitines are esters of carnitine responsible for the transport of long-chain fatty acids into mitochondria for β-oxidation, playing a crucial role in energy metabolism and lipid homeostasis. This study aimed to assess acylcarnitine and free fatty acid (FFA) profiles in PBC patients and their associations with fibrosis severity and inflammation.

Methods

This cross-sectional study included 46 PBC patients and 32 healthy controls. Acylcarnitines and FFAs were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and enzymatic assays, respectively. Liver stiffness was measured by point shear wave elastography (ElastPQ), and fibrosis was assessed using APRI and FIB-4 scores. Inflammatory markers (IL-6, IL-1β) were also analyzed.

Results

PBC patients had significantly higher levels of C18:1-acylcarnitine (median: 165.1 ng/mL) compared with the controls (152.4 ng/mL, p = 0.0036). Similarly, the FFA levels were markedly elevated in the PBC patients (median: 0.46 mM/L) compared with the controls (0.26 mM/L, p < 0.0001). Patients with higher liver stiffness (ElastPQ > 5.56 kPa) had significantly elevated C18:1-acylcarnitine (p = 0.0008) and FFA levels (p = 0.00098). Additionally, FFAs were significantly increased in patients with higher APRI and FIB-4 scores and were associated with elevated inflammatory markers (IL-6, IL-1β) and liver injury markers. Multivariate regression analysis confirmed C18:1-acylcarnitine (OR = 1.031, 95% CI: 1.007–1.057, p = 0.013) and FFAs (OR = 2.25 per 0.1 mM/L increase, 95% CI: 1.20–4.22, p = 0.012) as independent predictors of fibrosis severity in PBC.

Conclusions

C18:1-acylcarnitine and FFAs are significantly elevated in PBC and are strongly associated with fibrosis severity and inflammation. These findings suggest a link between lipid metabolism disturbances and PBC. Both metabolites may potentially serve as non-invasive biomarkers of fibrosis progression in PBC, warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarnitineLiver Cirrhosis, BiliaryInflammationFatty Acids, NonesterifiedLiver CirrhosisHumansMaleFemaleMiddle AgedCross-Sectional StudiesBiomarkersAdultAgedCase-Control StudiesElasticity Imaging Techniques

Stichwörter der Autor:innen

acylcarnitinesbile acidsfibrosisfree fatty acidsinflammationliver stiffnessmetabolic biomarkersmitochondrial dysfunctionprimary biliary cholangitisβ-oxidation

Substanzen

CarnitineacylcarnitineBiomarkersFatty Acids, Nonesterified

Autor:innen und Institutionen

  • Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 15-089 Białystok, Poland.
  • Hygiene, Epidemiology and Metabolic Disorders Department, Medical University of Bialystok, 15-089 Białystok, Poland.
  • Department of Medical Biology, Medical University of Bialystok, 15-089 Białystok, Poland.
  • Department of Pediatric Radiology, Medical University of Bialystok, 15-089 Białystok, Poland.
  • Faculty of Medicine, Medical University of Bialystok, 15-089 Białystok, Poland.
  • Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, 15-089 Białystok, Poland.

ORCID-Profile: Piotr Zabielski, Jacek Robert Janica, Robert Flisiak

Zitieren

APA

Rogalska, M., Błachnio-Zabielska, A., Zabielski, P., Janica, J. R., Roszczyc-Owsiejczuk, K., Pogodzińska, K., Andrzejuk, A., Dąbrowski, A., Flisiak, R., & Rogalski, P. (2025). Acylcarnitine and Free Fatty Acid Profiles in Primary Biliary Cholangitis: Associations with Fibrosis and Inflammation. Nutrients. https://doi.org/10.3390/nu17071097

Vancouver

Rogalska M, Błachnio-Zabielska A, Zabielski P, Janica JR, Roszczyc-Owsiejczuk K, Pogodzińska K, et al. Acylcarnitine and Free Fatty Acid Profiles in Primary Biliary Cholangitis: Associations with Fibrosis and Inflammation. Nutrients. 2025. doi:10.3390/nu17071097

BibTeX
@article{Rogalska2025,
  author = {Rogalska, Magdalena and Błachnio-Zabielska, Agnieszka and Zabielski, Piotr and Janica, Jacek Robert and Roszczyc-Owsiejczuk, Kamila and Pogodzińska, Karolina and Andrzejuk, Aleksandra and Dąbrowski, Andrzej and Flisiak, Robert and Rogalski, Paweł},
  title = {Acylcarnitine and Free Fatty Acid Profiles in Primary Biliary Cholangitis: Associations with Fibrosis and Inflammation},
  journal = {Nutrients},
  year = {2025},
  doi = {10.3390/nu17071097}
}
Kostenlos starten →